Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer

Jieying Li; Jianfei Huang; Fang Huang; Qing Jin; Huijun Zhu; Xudong Wang; Meng Chen

doi:10.18632/oncotarget.12039

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer

Jieying Li, Jianfei Huang, Fang Huang, Qing Jin, Huijun Zhu, Xudong Wang _ and Meng Chen

PDF | HTML | How to cite

Oncotarget. 2016; 7:73638-73650. https://doi.org/10.18632/oncotarget.12039

Metrics: PDF 1848 views | HTML 3847 views | ?

Abstract

Jieying Li1, Jianfei Huang1, Fang Huang1, Qing Jin1, Huijun Zhu1, Xudong Wang2, Meng Chen3

1Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China

2Department of Laboratory Medicine & Department of Clinical Tissue Bank, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China

3Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, USA

Correspondence to:

Xudong Wang, email: [email protected]

Keywords: gastrointestinal cancer, IDH1-R132H, prognosis, tissue microarray, immunohistochemistry

Received: April 25, 2016 Accepted: August 25, 2016 Published: September 15, 2016

ABSTRACT

Isocitrate dehydrogenase (IDH1) is an NADP-dependent enzyme that catalyzes the decarboxylation of isocitrate to alpha-ketoglutarate. The IDH1-R132H mutation predicts a better clinical outcome for glioma patients, and the expression of IDH1-R132H correlates with a favorable outcome in patients with brain tumors. Here, we investigated IDH1-R132H expression in both gastric (n=526) and colorectal (n=399) tissues by performing immunohistochemistry analyses on tissue microarrays. We also tested whether IDH1-R132H expression correlated with various clinical parameters. In both gastric and colorectal cancer, expression of IDH1-R132H was associated with tumor stage. Patients with low IDH1-R132H expression had a poor overall survival. Our data indicate that IDH1-R132H expression could be used as a predictive marker of prognosis for patients with gastrointestinal cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12039

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer

Abstract